Interestingly, in the CLL cybrid, treatment with Ibr + ALA (two-fold change, p < 0.0001), Ibr + Mel (2.4-fold change, p < 0.0001), and Ibr + Resv (3.4-fold change, p < 0.001) significantly increased BAX expression, whereas there was no change in response to Ibr + Amla treatment (Figure 6) Similarly, Ibr + ALA (two-fold change, p < 0.01), Ibr + Mel (3.5-fold change, p < 0.0001), and Ibr + Resv (4.1-fold change, p < 0.01) significantly increased the CASP3 expression, but there was no significant change in the expression of CASP3 in response to Ibr + Amla. This evidence concerns the gene BAX and B-cell chronic lymphocytic leukemia.